
Protalix BioTherapeutics PLX
€ 1.90
1.63%
Geschäftsbericht 2025
hinzugefügt 18.03.2026
Protalix BioTherapeutics Langfristiger Schuldenstrom 2011-2026 | PLX
Langfristiger Schuldenstrom Jährlich Protalix BioTherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.38 M | 1.5 M | 1.41 M | 1.12 M | 1.21 M | 1.42 M | 1.14 M | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.5 M | 1.12 M | 1.31 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 330.79 | 3.74 % | $ 43.3 B | ||
|
BioLineRx Ltd.
BLRX
|
522 K | $ 2.34 | 5.72 % | $ 908 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Aquestive Therapeutics
AQST
|
631 K | $ 4.11 | -0.48 % | $ 439 M | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
4.21 M | $ 8.24 | 2.55 % | $ 226 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Celldex Therapeutics
CLDX
|
1.55 M | $ 31.36 | 0.97 % | $ 2.08 B | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
Axcella Health
AXLA
|
1.59 M | - | -16.42 % | $ 249 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 23.46 | -0.72 % | $ 2.98 B | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
BioNTech SE
BNTX
|
45 M | $ 90.94 | -0.26 % | $ 27.2 B | ||
|
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | ||
|
Ardelyx
ARDX
|
1.48 M | $ 6.01 | 1.18 % | $ 1.45 B | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
CASI Pharmaceuticals
CASI
|
1.06 M | - | - | $ 35.4 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
argenx SE
ARGX
|
10.8 M | $ 749.21 | 0.37 % | $ 25 B |